Title | Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. |
Publication Type | Journal Article |
Year of Publication | 2007 |
Authors | Re VLo, Kostman JR, Gross R, K Reddy R, Mounzer K, Zemel BS, Rennert H, Stieritz DD, Putt M, Frank I, Strom BL |
Journal | J Acquir Immune Defic Syndr |
Volume | 44 |
Issue | 3 |
Pagination | 344-50 |
Date Published | 2007 Mar 01 |
ISSN | 1525-4135 |
Keywords | Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Antiviral Agents, Cohort Studies, Female, Hepatitis C, HIV Infections, Humans, Interferon alpha-2, Interferon-alpha, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Retrospective Studies, Ribavirin, Risk Factors, Weight Loss |
Abstract | BACKGROUND: Clinical observations suggest that patients with HIV/hepatitis C virus (HCV) may lose body weight during dual therapy, but this has not been confirmed analytically. OBJECTIVES: To determine if the incidence and degree of weight loss among patients with HIV/HCV receiving highly active antiretroviral therapy (HAART) and pegylated (PEG)-interferon plus ribavirin were greater than in (1) HCV-monoinfected patients receiving PEG-interferon plus ribavirin and (2) HIV-monoinfected patients receiving HAART. Risk factors for weight loss among patients with HIV/HCV were also examined. METHODS: A retrospective cohort study was performed among HIV/HCV-coinfected, HCV-monoinfected, and HIV-monoinfected patients. Body weights were assessed up to 6 months before and up to 12 months after initiation of HCV therapy (HIV/HCV-coinfected and HCV-monoinfected subjects) and over 18 months on HAART (HIV-monoinfected subjects). The primary outcome was clinically significant weight loss (> or =5% of baseline weight). RESULTS: Of 192 subjects, 63 had HIV/HCV, 64 had HCV alone, and 65 had HIV alone. Clinically significant weight loss occurred in 48 (76%) subjects with HIV/HCV versus 25 (39%) subjects with HCV (P < 0.001) and 2 (3%) subjects with HIV (P < 0.001), yielding adjusted hazard ratios (HRs) of 2.76 (95% confidence interval [CI]: 1.67 to 4.55) and 38.5 (95% CI: 8.5 to 174.7), respectively. Receipt of more than 2 nucleoside reverse transcriptase inhibitors increased the risk of clinically significant weight loss (adjusted HR = 8.17, 95% CI: 2.37 to 28.20). CONCLUSIONS: The incidence of weight loss is greater in dually treated patients with HIV/HCV than in treated HCV- or HIV-monoinfected patients. Prospective studies should evaluate additional risk factors for weight loss and changes in body composition to elucidate the mechanism for this weight loss. |
DOI | 10.1097/QAI.0b013e31802f12d3 |
Alternate Journal | J Acquir Immune Defic Syndr |
PubMed ID | 17179767 |
Grant List | P30 AI 45008 / AI / NIAID NIH HHS / United States U01 AI 32783 / AI / NIAID NIH HHS / United States T32 AI 055435 / AI / NIAID NIH HHS / United States F32 DK 069080 / DK / NIDDK NIH HHS / United States HS 10399 / HS / AHRQ HHS / United States K08 MH 01584 / MH / NIMH NIH HHS / United States |
Related Faculty:
Hanna Rennert, Ph.D.